Тиреоидный статус как прогностический маркер в онкологии

Тиреоидный статус как прогностический маркер в онкологии

Автор: Глушаков Р.И., Власьева О.В., Соболев И.В., Прошин С.Н., Тапильская Н.И.

Журнал: Злокачественные опухоли @malignanttumors

Рубрика: Диагностика и лечение опухолей. Состояние проблемы

Статья в выпуске: 2 (13), 2015 года.

Бесплатный доступ

В обзоре представлены данные о негеномных свойствах тиреоидных гормонов (ТГ), начало которым дают внеклеточные домены белка клеточной адгезии - интегрина V3, в результате чего происходит активация митогенактивируемой протеинкиназы, фосфотидил-инозитол-3-киназы. Конечными эффектами негеномного действия являются активация клеточной пролиферации, ангиогенеза и миграции клеток, а также повышение экспрессии тканеспецифичных генов воспаления. Также приведены данные влияния клинических исследований, в которых прослежено увеличение ответа на лечение и увеличение выживаемости у онкологических больных с индуцированным гипотиреозом.

Негеномные эффекты тиреоидных гормонов, индуцированный гипотиреоз

Короткий адрес: https://sciup.org/14045526

IDR: 14045526

Список литературы Тиреоидный статус как прогностический маркер в онкологии

  • Aghajanova L., Lindeberg M., Carlson I. B. et al. Receptors for thyroid-stimulating hormone and thyroid hormones in human ovarian tissue//Reprod. Biomed. Online. 2009; 18 (3): 337-347
  • Ashur-Fabian O., Blumenthal D. T., Bakon M. et al. Long-term response in high-grade optic glioma treated with medically induced hypothyroidism and carboplatin: a case report and review of the literature//Anticancer Drugs. 2013; 24 (3): 315-23
  • Balkwill F., Charles K. A., Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease//Cancer Cell. 2005; 7
  • Billon N., Terrinoni A., Jolicoeur C. et al. Roles for p53 and p73 during oligodendrocyte Development//Development. 2004; 131: 1211-20
  • Brown R. L. Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management//Target Oncol. 2011; 6 (4): 217-26
  • Cao X., Kambe F., Moeller L. C. et al. Thyroid hormone induces rapid activation of Akt/protein kinase B-mammalian target of rapamycin-p70S6K cascade through phosphatidylinositol 3-kinase in human fibroblasts//Mol. Endocrinol. 2005; 19 (1): 102-112
  • Carvalho A. F., Dimellis D., Gonda X. et al. Rapid cycling in bipolar disorder: a systematic review//J Clin Psychiatry. 2014; 75 (6): e578-86
  • Cohen K., Ellis M., Khoury S. et al. Thyroid hormone is a MAPK-dependent growth factor for human myeloma cells acting via v3 integrin//Mol. Cancer Res. 2011; 9 (10): 1385-94
  • Crile G. Jr. The endocrine dependency of certain thyroid Cancers and the danger that hypothyroidism may stimulate their growth//Cancer. 1957; 10 (6): 1119-37
  • Davis F. B., Tang H. Y., Shih A. et al. Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells//Cancer Res. 2006; 66 (14): 7270-7275
  • Davis F. B., Mousa S. A., O’Connor L. et al. Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface//Circ. Res. 2004; 94 (11): 1500-1506
  • Davis P. J., Lin H. Y., Tang H. Y. et al. Adjunctive input to the nuclear Thyroid hormone receptor from the cell surface receptor for the hormone//Thyroid. 2013; 23 (12): 1503-9
  • Demartini B., Ranieri R., Masu A. et al. Depressive symptoms and major depressive disorder in patients affected by subclinical hypothyroidism: a cross-sectional study//J Nerv Ment Dis. 2014; 202 (8): 603-7
  • Faber J, Selmer C. Cardiovascular disease and thyroid function//Front Horm Res. 2014; 43: 45-56
  • Farwell A. P., Dubord-Tomasetti S.A., Pietrzykowski A. Z., Leonard J. L. Regulation of cerebellar neuronal migration and neurite outgrowth by thyroxine and 3,3»,5’-triiodothyronine//Brain Res. Dev. Brain Res. 2005; 154 (11): 121-135
  • Hercbergs A. A., Suh J. H., Lee S. et al. Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study//Anticancer Res. 2003; 23 (1B): 617-626
  • Huang S. A. Physiology and pathophysiology of type 3 deiodinase in humans//Thyroid.-2005; 15 (8): 875-881
  • Humphrey L. J., Swerdlow M. The relationship of breast disease to thyroid disease//Cancer. 1964; 17: 1170-3
  • Linetsky E., Hercbergs A. A., Dotan S. et al. Time to tumor progression (TTP) and quality of life (QOL) following propylthiouracil induction of chemical hypothyroidism in failed malignant gliomas//Abstracts from the World Federation of Neuro-Oncology Second Quadrennial Meeting and the Sixth Meeting of the European Association for Neuro-Oncology: Edinburgh, U.K. 2005: 318
  • Lodish M. B., Stratakis C. A. Endocrine side effects of broad-acting kinase inhibitors//Endocr Relat Cancer. 2010; 17 (3): R233-44
  • Moeller L. C., Dumitrescu A. M., Walker R. L. et al. Thyroid hormone responsive genes in cultured human fibroblasts//J. Clin. Endocrinol. Metab. 2005: 90 (2): 936-943
  • Nelson M., Hercbergs A., Rybicki L., Strome M. Association between development of hypothyroidism and improved survival in patients with head and neck cancer//Arch Otolaryngol Head Neck Surg. 2006; 132 (10): 1041-6
  • Rae M. T., Gubbay O., Kostogiannou A. et al. Thyroid hormone signaling in human ovarian surface epithelial cells//J. Clin. Endocrinol. Metab. 2007.; 92 (1): 322-327
  • Reid I., Sharpe I., McDevitt J. et al. Thyroid dysfunction can predict response to immunotherapy with interleukin-2 and interferon-2 alpha//Br J Cancer. 1991; 64 (5): 915-8
  • Riesenbeck L. M., Bierer S., Hoffmeister I. et al. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib//World J Urol. 2011; 29 (6): 807-13
  • Russfield A. B. Histology of the human hypophysis in thyroid disease-hypothyroidism, hyperthyroidism, and cancer//J Clin Endocrinol Metab. 1955; 15 (11): 1393-408
  • Sabatier R., Eymard J. C., Walz J. et al. Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?//Ann Oncol. 2012; 23 (3): 714-21
  • Schmidinger M., Vogl U. M., Bojic M. et al. Hypothyroidism in patients with renal cell modifier genes and implications for screening//J. Med. Genet.-2007.-V. 44.-P. 10-15.
  • Schwartz M. A. Integrin signaling revisited//Trends Cell Biol. 2001; 11: 466-470
  • Shih C., Chen S., Yen C. et al. Thyroid hormone receptor-dependent transcriptional regulation of fibrinogen and coagulation proteins//Endocrinology. 2004; 145: 2804-2814
  • Siegrist-Kaiser C.A., Juge-Aubry C., Tranter M. P. et al. Thyroxine-dependent modulation of actin polymerization in cultured astrocytes. A novel extranuclear action of thyroid hormone//J. Biol. Chem. 1990; 265: 5296-5302
  • Smith T. G., Roblins P. A., Ratelife P. J. The human side of hypoxia-inducible factor//Brit. J. Haemot. 2008; 141: 325-334
  • Tang H. Y., Lin H. Y., Zhang S. et al. Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor//Endocrinology. 2004; 145: 3265-3272
  • Viguerie N., Millet L., Avizou S. et al. Regulation of human adipocyte gene expression by thyroid hormone//J. Clin. Endocrinol. Metab. 2002; 87: 630-634
  • Wang X., Page-McCaw A. A matrix metalloproteinase mediates long-distance attenuation of stem cell proliferation//J Cell Biol. 2014; 206 (7): 923-36
  • Weijl N. I., Van der Harst D., Brand A. et al. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment//J Clin Oncol. 1993; 11 (7): 1376-83
  • Wolter P., Stefan C., Decallonne B. et al. Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC)//ASCO Meeting Abstracts 5126, 2008
  • References
  • Aghajanova L., Lindeberg M., Carlson I. B. et al. Receptors for thyroid-stimulating hormone and thyroid hormones in human ovarian tissue//Reprod. Biomed. Online. 2009; 18 (3): 337-347
  • Ashur-Fabian O., Blumenthal D. T., Bakon M. et al. Long-term response in high-grade optic glioma treated with medically induced hypothyroidism and carboplatin: a case report and review of the literature//Anticancer Drugs. 2013; 24 (3): 315-23
  • Balkwill F., Charles K. A., Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease//Cancer Cell. 2005; 7: 211-217
  • Billon N., Terrinoni A., Jolicoeur C. et al. Roles for p53 and p73 during oligodendrocyte Development//Development. 2004; 131: 1211-20
  • Brown R. L. Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management//Target Oncol. 2011; 6 (4): 217-26
  • Cao X., Kambe F., Moeller L. C. et al. Thyroid hormone induces rapid activation of Akt/protein kinase B-mammalian target of rapamycin-p70S6K cascade through phosphatidylinositol 3-kinase in human fibroblasts//Mol. Endocrinol. 2005; 19 (1): 102-112
  • Carvalho A. F., Dimellis D., Gonda X. et al. Rapid cycling in bipolar disorder: a systematic review//J Clin Psychiatry. 2014; 75 (6): e578-86
  • Cohen K., Ellis M., Khoury S. et al. Thyroid hormone is a MAPK-dependent growth factor for human myeloma cells acting via v3 integrin//Mol. Cancer Res. 2011; 9 (10): 1385-94
  • Crile G. Jr. The endocrine dependency of certain thyroid Cancers and the danger that hypothyroidism may stimulate their growth//Cancer. 1957; 10 (6): 1119-37
  • Davis F. B., Tang H. Y., Shih A. et al. Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells//Cancer Res. 2006; 66 (14): 7270-7275
  • Davis F. B., Mousa S. A., O’Connor L. et al. Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface//Circ. Res. 2004; 94 (11): 1500-1506
  • Davis P. J., Lin H. Y., Tang H. Y. et al. Adjunctive input to the nuclear Thyroid hormone receptor from the cell surface receptor for the hormone//Thyroid. 2013; 23 (12): 1503-9
  • Demartini B., Ranieri R., Masu A. et al. Depressive symptoms and major depressive disorder in patients affected by subclinical hypothyroidism: a cross-sectional study//J Nerv Ment Dis. 2014; 202 (8): 603-7.
  • Faber J, Selmer C. Cardiovascular disease and thyroid function//Front Horm Res. 2014; 43: 45-56
  • Farwell A. P., Dubord-Tomasetti S.A., Pietrzykowski A. Z., Leonard J. L. Regulation of cerebellar neuronal migration and neurite outgrowth by thyroxine and 3,3»,5’-triiodothyronine//Brain Res. Dev. Brain Res. 2005; 154 (11): 121-135
  • Hercbergs A. A., Suh J. H., Lee S. et al. Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study//Anticancer Res. 2003; 23 (1B): 617-626
  • Huang S. A. Physiology and pathophysiology of type 3 deiodinase in humans//Thyroid.-2005; 15 (8): 875-881
  • Humphrey L. J., Swerdlow M. The relationship of breast disease to thyroid disease//Cancer. 1964; 17: 1170-3
  • Linetsky E., Hercbergs A. A., Dotan S. et al. Time to tumor progression (TTP) and quality of life (QOL) following propylthiouracil induction of chemical hypothyroidism in failed malignant gliomas//Abstracts from the World Federation of Neuro-Oncology Second Quadrennial Meeting and the Sixth Meeting of the European Association for Neuro-Oncology: Edinburgh, U.K. 2005: 318
  • Lodish M. B., Stratakis C. A. Endocrine side effects of broad-acting kinase inhibitors//Endocr Relat Cancer. 2010; 17 (3): R233-44
  • Moeller L. C., Dumitrescu A. M., Walker R. L. et al. Thyroid hormone responsive genes in cultured human fibroblasts//J. Clin. Endocrinol. Metab. 2005: 90 (2): 936-943
  • Nelson M., Hercbergs A., Rybicki L., Strome M. Association between development of hypothyroidism and improved survival in patients with head and neck cancer//Arch Otolaryngol Head Neck Surg. 2006; 132 (10): 1041-6
  • Rae M. T., Gubbay O., Kostogiannou A. et al. Thyroid hormone signaling in human ovarian surface epithelial cells//J. Clin. Endocrinol. Metab. 2007.; 92 (1): 322-327
  • Reid I., Sharpe I., McDevitt J. et al. Thyroid dysfunction can predict response to immunotherapy with interleukin-2 and interferon-2 alpha//Br J Cancer. 1991; 64 (5): 915-8
  • Riesenbeck L. M., Bierer S., Hoffmeister I. et al. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib//World J Urol. 2011; 29 (6): 807-13
  • Russfield A. B. Histology of the human hypophysis in thyroid disease-hypothyroidism, hyperthyroidism, and cancer//J Clin Endocrinol Metab. 1955; 15 (11): 1393-408
  • Sabatier R., Eymard J. C., Walz J. et al. Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?//Ann Oncol. 2012; 23 (3): 714-21
  • Schmidinger M., Vogl U. M., Bojic M. et al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse?//Cancer. 2011; 117 (3): 534-44
  • Schwartz M. A. Integrin signaling revisited//Trends Cell Biol. 2001; 11: 466-470
  • Shih C., Chen S., Yen C. et al. Thyroid hormone receptor-dependent transcriptional regulation of fibrinogen and coagulation proteins//Endocrinology. 2004; 145: 2804-2814
  • Siegrist-Kaiser C.A., Juge-Aubry C., Tranter M. P. et al. Thyroxine-dependent modulation of actin polymerization in cultured astrocytes. A novel extranuclear action of thyroid hormone//J. Biol. Chem. 1990; 265: 5296-5302
  • Smith T. G., Roblins P. A., Ratelife P. J. The human side of hypoxia-inducible factor//Brit. J. Haemot. 2008; 141: 325-334
  • Tang H. Y., Lin H. Y., Zhang S. et al. Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor//Endocrinology. 2004; 145: 3265-3272
  • Viguerie N., Millet L., Avizou S. et al. Regulation of human adipocyte gene expression by thyroid hormone//J. Clin. Endocrinol. Metab. 2002; 87: 630-634
  • Wang X., Page-McCaw A. A matrix metalloproteinase mediates long-distance attenuation of stem cell proliferation//J Cell Biol. 2014; 206 (7): 923-36
  • Weijl N. I., Van der Harst D., Brand A. et al. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment//J Clin Oncol. 1993; 11 (7): 1376-83
  • Wolter P., Stefan C., Decallonne B. et al. Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC)//ASCO Meeting Abstracts 5126, 2008
Еще
Статья научная
SciUp 2024 © 2024 ©